Kymera Therapeutics (KYMR) Net Margin (2019 - 2026)
Kymera Therapeutics (KYMR) reported Net Margin of 201.47% for Q1 2026, up 9528.0% year-over-year from 2.09% in Q1 2025, and up 93.35% quarter-over-quarter from 3030.7% in Q4 2025.
Kymera Therapeutics (KYMR) Net Margin (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has 8 years of Net Margin data on file, last reported at 201.47% in Q1 2026.
- Net Margin for Q1 2026 came in at 201.47%, up 9528.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 611.96% (down 20288.0% YoY), and the FY2025 annual result was 794.04%, down 31847.0% from the prior year.
- Net Margin improved to 201.47% in Q1 2026 per KYMR's latest filing, from 3030.7% in the prior quarter.
- Over five years, Net Margin peaked at 30.01% in Q4 2023 and troughed at 3030.7% in Q4 2025.
- A 5-year average of 802.85% and a median of 432.37% in 2023 frame the typical range for Net Margin.
- The sharpest annual moves came in 2023 and 2025: Net Margin jumped 18602 bps in 2023, then slumped 207381 bps in 2025.
- A 5-year view of Net Margin shows it stood at 216.03% in 2022, then jumped by 86 bps to 30.01% in 2023, then sank by 3089 bps to 956.88% in 2024, then slumped by 217 bps to 3030.7% in 2025, then surged by 93 bps to 201.47% in 2026.
- Business Quant data shows KYMR's Net Margin at 201.47% in Q1 2026, 3030.7% in Q4 2025, and 2973.05% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.82% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 34.53% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Kymera Therapeutics | 8.84 Bn | 8.19 Bn | - | -201.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -201.47% |
| Dec 31, 2025 | -3,030.70% |
| Sep 30, 2025 | -2,973.05% |
| Jun 30, 2025 | -667.60% |
| Mar 31, 2025 | -296.75% |
| Dec 31, 2024 | -956.88% |
| Sep 30, 2024 | -1,670.33% |
| Jun 30, 2024 | -163.98% |
| Mar 31, 2024 | -472.02% |
| Dec 31, 2023 | -30.01% |
| Sep 30, 2023 | -1,118.17% |
| Jun 30, 2023 | -234.96% |
| Mar 31, 2023 | -432.37% |
| Dec 31, 2022 | -216.03% |
| Sep 30, 2022 | -450.24% |
| Jun 30, 2022 | -349.64% |
| Mar 31, 2022 | -384.27% |
| Dec 31, 2021 | -222.88% |
| Sep 30, 2021 | -141.16% |
| Jun 30, 2021 | -133.16% |